Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 – Full Year 2020 Year-Over-Year: – Product Sales increased 10% to $24.4 billion, primarily due to Veklury – – Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 – – Returned $5.0 billion of cash to shareholders through dividends and share repurchases – Full Year 2021 Guidance: – Product Sales including Veklury of $23.7 billion to $25.1 billion – – Operating …
– Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 – Full Year 2020 Year-Over-Year: – Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 – – Returned $5.0 billion of cash to shareholders through dividends and share repurchases – Full Year 2021 Guidance: – Operating expenses flat to low single-digit percentage decline – – Non-GAAP Diluted EPS of $6.75 to $7.45 –
We re #33!: TSX ekes out gain in pandemic-ravaged 2020
Ian Vandaelle, BNN Bloomberg VIDEO SIGN OUT
2020 will go down in financial market history as one of the most dramatic years on record.
The global pandemic prompted unprecedented lockdowns, a tsunami of fiscal and monetary stimulus, and the most volatile swings on equity markets in a generation. Torontoâs benchmark S&P/TSX Composite Index plunged 37 per cent from peak to trough, then clawed its way back to post a 2.17 per cent gain in 2020. Thatâs good for 33rd out of 92 major global indices, with the TSX sandwiched between Malaysia and Norway in terms of total 2020 returns, but badly lagging the 16 per cent return on the S&P 500 as surging tech stocks turbocharged the bounceback south of the border.
Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.